Abstract
The field of cell therapy for cardiovascular disease has progressed at an uneven rate and will likely follow the translational paths of other biologic therapies. The field will require novel public-private partnerships to guide it to its ultimate applications.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Biological Products / therapeutic use*
-
Cardiovascular Diseases / pathology
-
Cardiovascular Diseases / physiopathology
-
Cardiovascular Diseases / therapy*
-
Cell- and Tissue-Based Therapy / methods*
-
Cell- and Tissue-Based Therapy / trends
-
Humans